Featured Research

from universities, journals, and other organizations

New Low-Cost Vaccine Offers Better Protection Against Cholera

Date:
February 15, 2002
Source:
World Health Organization
Summary:
Trials of a cholera vaccine manufactured in Viet Nam at a cost of about only 20 US cents a dose have produced encouraging results, especially for children, an international team of researchers reports in the latest issue of the Bulletin of the World Health Organization. The team, headed by Professor Dang Duc Trach at the National Institute of Hygiene and Epidemiology in Hanoi, concluded that the vaccine was "safe and immunogenic" and "could elicit robust immune responses".

Trials of a cholera vaccine manufactured in Viet Nam at a cost of about only 20 US cents a dose have produced encouraging results, especially for children, an international team of researchers reports in the latest issue of the Bulletin of the World Health Organization. The team, headed by Professor Dang Duc Trach at the National Institute of Hygiene and Epidemiology in Hanoi, concluded that the vaccine was "safe and immunogenic" and "could elicit robust immune responses".

The vaccine was found to offer elicit high levels of immunity in children, for whom the risk of endemic cholera is highest, as well as in adults. These responses were comparable to those elicited by a Swedish-made vaccine that has already been licensed for use in several European countries.

Work began in Viet Nam during the mid-1980s on the production of a killed oral cholera whole-cell vaccine that could be used in the country's public health programmes. The vaccine was later modified so that it could also counter a new form of epidemic cholera that emerged in the 1990s.

The two trials reported in the Bulletin were carried out in Hanoi and involved about 144 adults aged between 17 and 25 years and about 103 children aged 1-12 years. The trials were conducted by scientists from Viet Nam, Sweden, the United States, the Republic of Korea, the International Vaccine Institute in South Korea and the World Health Organization in Switzerland.

All the participants were given two doses of either the locally-produced vaccine, its Swedish counterpart, or a placebo, with the doses separated by an interval of two weeks. The trial in children began only after the trial in adults showed no important side-effects.

In both studies, the participants were observed for 30 minutes after each dose and were visited daily for three consecutive days to ascertain symptoms. Interviews were also conducted two weeks after each dose in order to obtain information about any intervening illnesses requiring medical care. Blood samples were taken for laboratory analysis.

The researchers found that the Vietnamese vaccine was associated with no side-effects and caused a better immune response in children than in adults, for reasons that were not clear. "The safety and immunogenicity of the vaccine, especially its ability to elicit robust responses, are encouraging, particularly because of its low cost of production (ca. US$ 0.20 per dose) in Viet Nam," the scientists say in the journal. They add that further studies are needed in order to evaluate the clinical protection it confers.


Story Source:

The above story is based on materials provided by World Health Organization. Note: Materials may be edited for content and length.


Cite This Page:

World Health Organization. "New Low-Cost Vaccine Offers Better Protection Against Cholera." ScienceDaily. ScienceDaily, 15 February 2002. <www.sciencedaily.com/releases/2002/02/020215070457.htm>.
World Health Organization. (2002, February 15). New Low-Cost Vaccine Offers Better Protection Against Cholera. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2002/02/020215070457.htm
World Health Organization. "New Low-Cost Vaccine Offers Better Protection Against Cholera." ScienceDaily. www.sciencedaily.com/releases/2002/02/020215070457.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins